The	O
intracellular	O
parasite	O
Theileria	O
parva	O
protects	O
infected	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
apoptosis	O
.	O

Parasites	O
have	O
evolved	O
a	O
plethora	O
of	O
strategies	O
to	O
ensure	O
their	O
survival	O
.	O

The	O
intracellular	O
parasite	O
Theileria	O
parva	O
secures	O
its	O
propagation	O
and	O
spreads	O
through	O
the	O
infected	O
animal	O
by	O
infecting	O
and	O
transforming	O
T	B-cell_type
cells	I-cell_type
,	O
inducing	O
their	O
continuous	O
proliferation	O
and	O
rendering	O
them	O
metastatic	O
.	O

In	O
previous	O
work	O
,	O
we	O
have	O
shown	O
that	O
the	O
parasite	O
induces	O
constitutive	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
,	O
by	O
inducing	O
the	O
constitutive	O
degradation	O
of	O
its	O
cytoplasmic	B-protein
inhibitors	I-protein
.	O

The	O
biological	O
significance	O
of	O
NF-kappaB	B-protein
activation	O
in	O
T.	B-cell_type
parva-infected	I-cell_type
cells	I-cell_type
,	O
however	O
,	O
has	O
not	O
yet	O
been	O
defined	O
.	O

Cells	O
that	O
have	O
been	O
transformed	O
by	O
viruses	O
or	O
oncogenes	B-DNA
can	O
persist	O
only	O
if	O
they	O
manage	O
to	O
avoid	O
destruction	O
by	O
the	O
apoptotic	O
mechanisms	O
that	O
are	O
activated	O
on	O
transformation	O
and	O
that	O
contribute	O
to	O
maintain	O
cellular	O
homeostasis	O
.	O

We	O
now	O
demonstrate	O
that	O
parasite-induced	O
NF-kappaB	B-protein
activation	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
survival	O
of	O
T.	B-cell_type
parva-transformed	I-cell_type
T	I-cell_type
cells	I-cell_type
by	O
conveying	O
protection	O
against	O
an	O
apoptotic	O
signal	O
that	O
accompanies	O
parasite-mediated	O
transformation	O
.	O

Consequently	O
,	O
inhibition	O
of	O
NF-kappaB	B-protein
nuclear	O
translocation	O
and	O
the	O
expression	O
of	O
dominant	B-protein
negative	I-protein
mutant	I-protein
forms	O
of	O
components	O
of	O
the	O
NF-kappaB	B-protein
activation	O
pathway	O
,	O
such	O
as	O
IkappaBalpha	B-protein
or	O
p65	B-protein
,	O
prompt	O
rapid	O
apoptosis	O
of	O
T.	B-cell_type
parva-transformed	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Our	O
findings	O
offer	O
important	O
insights	O
into	O
parasite	O
survival	O
strategies	O
and	O
demonstrate	O
that	O
parasite-induced	O
constitutive	O
NF-kappaB	B-protein
activation	O
is	O
an	O
essential	O
step	O
in	O
maintaining	O
the	O
transformed	O
phenotype	O
of	O
the	O
infected	B-cell_type
cells	I-cell_type
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

96	NULL
,	NULL
pp	NULL
.	NULL

7312-7317	NULL
,	NULL
June	NULL
1999	NULL
Cell	NULL
Biology	NULL
The	NULL
intracellular	NULL
parasite	NULL
Theileria	NULL
parva	NULL
protects	NULL
infected	NULL
T	NULL
cells	NULL
from	NULL
apoptosis	NULL
VoLKER	NULL
T.	NULL
HEUSSLER*	NULL
,	NULL
JOEL	NULL
MAcHADo	NULL
,	NULL
JR	NULL
*	NULL
,	NULL
PAULA	NULL
C.	NULL
FERNANDEZ*	NULL
,	NULL
CATHERINE	NULL
BOTTERON®*	NULL
,	NULL
CHao-GuaANG	NULL
CHENT	NULL
,	NULL
Martin	NULL
J.	NULL
PEaARsET	NULL
,	NULL
AND	NULL
DIRK	NULL
A.	NULL
E.	NULL
DOBBELAERE**	NULL
*Laboratory	NULL
of	NULL
Immunopathology	NULL
,	NULL
Institute	NULL
of	NULL
Animal	NULL
Pathology	NULL
,	NULL
University	NULL
of	NULL
Berne	NULL
,	NULL
CH-3012	NULL
Berne	NULL
,	NULL
Switzerland	NULL
;	NULL
and	NULL
*Immunology	NULL
Research	NULL
Centre	NULL
,	NULL
St.	NULL
Vincent	NULL
's	NULL
Hospital	NULL
,	NULL
Melbourne	NULL
,	NULL
Fitzroy	NULL
3065	NULL
,	NULL
Victoria	NULL
,	NULL
Australia	NULL
Communicated	NULL
by	NULL
Don	NULL
W.	NULL
Fawcett	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
,	NULL
April	NULL
28	NULL
,	NULL
1999	NULL
(	NULL
received	NULL
for	NULL
review	NULL
March	NULL
1	NULL
,	NULL
1999	NULL
)	NULL
ABSTRACT	NULL
Parasites	NULL
have	NULL
evolved	NULL
a	NULL
plethora	NULL
of	NULL
strategies	NULL
to	NULL
ensure	NULL
their	NULL
survival	NULL
.	NULL

The	NULL
intracellular	NULL
parasite	NULL
Theileria	NULL
parva	NULL
secures	NULL
its	NULL
propagation	NULL
and	NULL
spreads	NULL
through	NULL
the	NULL
infected	NULL
animal	NULL
by	NULL
infecting	NULL
and	NULL
transforming	NULL
T	NULL
cells	NULL
,	NULL
inducing	NULL
their	NULL
continuous	NULL
proliferation	NULL
and	NULL
rendering	NULL
them	NULL
meta-static	NULL
.	NULL

In	NULL
previous	NULL
work	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
parasite	NULL
induces	NULL
constitutive	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NF-xB	NULL
,	NULL
by	NULL
inducing	NULL
the	NULL
constitutive	NULL
degradation	NULL
of	NULL
its	NULL
cytoplasmic	NULL
inhibitors	NULL
.	NULL

The	NULL
biological	NULL
significance	NULL
of	NULL
NF-KB	NULL
activation	NULL
in	NULL
7.	NULL
parve-infected	NULL
cells	NULL
,	NULL
however	NULL
,	NULL
has	NULL
not	NULL
yet	NULL
been	NULL
defined	NULL
.	NULL

Cells	NULL
that	NULL
have	NULL
been	NULL
transformed	NULL
by	NULL
viruses	NULL
or	NULL
oncogenes	NULL
can	NULL
persist	NULL
only	NULL
if	NULL
they	NULL
manage	NULL
to	NULL
avoid	NULL
destruction	NULL
by	NULL
the	NULL
apoptotic	NULL
mechanisms	NULL
that	NULL
are	NULL
activated	NULL
on	NULL
transformation	NULL
and	NULL
that	NULL
contribute	NULL
to	NULL
maintain	NULL
cellular	NULL
homeostasis	NULL
.	NULL

We	NULL
now	NULL
demonstrate	NULL
that	NULL
parasite-induced	NULL
NF-xB	NULL
activation	NULL
plays	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
the	NULL
survival	NULL
of	NULL
7.	NULL
parva-transformed	NULL
T	NULL
cells	NULL
by	NULL
conveying	NULL
protection	NULL
against	NULL
an	NULL
apoptotic	NULL
signal	NULL
that	NULL
accompanies	NULL
parasite-mediated	NULL
transformation	NULL
.	NULL

Conse-quently	NULL
,	NULL
inhibition	NULL
of	NULL
NF-xB	NULL
nuclear	NULL
translocation	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
dominant	NULL
negative	NULL
mutant	NULL
forms	NULL
of	NULL
components	NULL
of	NULL
the	NULL
NF-KB	NULL
activation	NULL
pathway	NULL
,	NULL
such	NULL
as	NULL
IBa	NULL
or	NULL
p65	NULL
,	NULL
prompt	NULL
rapid	NULL
apoptosis	NULL
of	NULL
T.	NULL
parva-transformed	NULL
T	NULL
cells	NULL
.	NULL

Our	NULL
findings	NULL
offer	NULL
important	NULL
insights	NULL
into	NULL
parasite	NULL
survival	NULL
strategies	NULL
and	NULL
demonstrate	NULL
that	NULL
parasite-induced	NULL
constitutive	NULL
NF-KB	NULL
activation	NULL
is	NULL
an	NULL
essential	NULL
step	NULL
in	NULL
maintaining	NULL
the	NULL
transformed	NULL
phenotype	NULL
of	NULL
the	NULL
infected	NULL
cells	NULL
.	NULL

Theileria	NULL
parva	NULL
is	NULL
an	NULL
intracellular	NULL
protozoan	NULL
parasite	NULL
that	NULL
is	NULL
transmitted	NULL
by	NULL
ticks	NULL
and	NULL
causes	NULL
East	NULL
Coast	NULL
fever	NULL
,	NULL
a	NULL
lympho-proliferative	NULL
disorder	NULL
of	NULL
cattle	NULL
in	NULL
East	NULL
and	NULL
Central	NULL
Africa	NULL
(	NULL
1	NULL
)	NULL
.	NULL

T.	NULL
parva-induced	NULL
T-cell	NULL
transformation	NULL
is	NULL
the	NULL
predominant	NULL
mechanism	NULL
underlying	NULL
the	NULL
pathogenesis	NULL
of	NULL
East	NULL
Coast	NULL
fever	NULL
.	NULL

Upon	NULL
invasion	NULL
by	NULL
the	NULL
parasite	NULL
,	NULL
T	NULL
cells	NULL
undergo	NULL
lymphoblastoid	NULL
transformation	NULL
(	NULL
2	NULL
)	NULL
,	NULL
become	NULL
independent	NULL
of	NULL
antigen	NULL
receptor	NULL
stimulation	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
,	NULL
and	NULL
cease	NULL
to	NULL
require	NULL
exogenous	NULL
growth	NULL
factors	NULL
to	NULL
proliferate	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
.	NULL

T.	NULL
parva-transformed	NULL
T	NULL
cells	NULL
show	NULL
many	NULL
characteristics	NULL
of	NULL
tumor	NULL
cells	NULL
,	NULL
including	NULL
unlimited	NULL
proliferation	NULL
in	NULL
vitro	NULL
,	NULL
clonal	NULL
expansion	NULL
,	NULL
the	NULL
formation	NULL
of	NULL
invasive	NULL
tumors	NULL
in	NULL
nude	NULL
mice	NULL
,	NULL
and	NULL
lesions	NULL
resembling	NULL
multicentric	NULL
lymphosarcoma	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
exact	NULL
mode	NULL
of	NULL
transformation	NULL
has	NULL
not	NULL
yet	NULL
been	NULL
elucidated	NULL
,	NULL
a	NULL
number	NULL
of	NULL
host	NULL
cell	NULL
kinases	NULL
,	NULL
such	NULL
as	NULL
Src-family	NULL
kinases	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
,	NULL
jun-NH	NULL
>	NULL
-terminal	NULL
kinase	NULL
(	NULL
4	NULL
,	NULL
11	NULL
)	NULL
,	NULL
and	NULL
casein	NULL
kinase	NULL
II	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
,	NULL
with	NULL
important	NULL
functions	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
T-cell	NULL
activation	NULL
,	NULL
proliferation	NULL
,	NULL
and	NULL
transformation	NULL
have	NULL
been	NULL
found	NULL
to	NULL
be	NULL
activated	NULL
in	NULL
a	NULL
parasite-dependent	NULL
manner	NULL
in	NULL
7.	NULL
parva-transformed	NULL
T	NULL
cells	NULL
(	NULL
9	NULL
,	NULL
14	NULL
,	NULL
15	NULL
)	NULL
.	NULL

A	NULL
unique	NULL
aspect	NULL
of	NULL
T.	NULL
parva-induced	NULL
transformation	NULL
is	NULL
that	NULL
it	NULL
is	NULL
entirely	NULL
reversible	NULL
(	NULL
5	NULL
,	NULL
16	NULL
)	NULL
.	NULL

Continuous	NULL
proliferation	NULL
depends	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
T.	NULL
parva	NULL
in	NULL
the	NULL
host	NULL
cell	NULL
cytoplasm	NULL
.	NULL

When	NULL
the	NULL
parasite	NULL
is	NULL
eliminated	NULL
by	NULL
treatment	NULL
with	NULL
the	NULL
specific	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

PNAS	NULL
is	NULL
available	NULL
online	NULL
at	NULL
www.pnas.org	NULL
.	NULL

7312	NULL
theilericidal	NULL
drug	NULL
BW720c	NULL
,	NULL
cells	NULL
revert	NULL
to	NULL
a	NULL
resting	NULL
phenotype	NULL
over	NULL
a	NULL
period	NULL
of	NULL
3-4	NULL
days	NULL
(	NULL
5	NULL
)	NULL
and	NULL
eventually	NULL
undergo	NULL
apoptosis	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Apoptosis	NULL
is	NULL
a	NULL
widespread	NULL
mechanism	NULL
that	NULL
is	NULL
central	NULL
to	NULL
the	NULL
maintenance	NULL
of	NULL
cellular	NULL
homeostasis	NULL
in	NULL
all	NULL
tissues	NULL
,	NULL
including	NULL
the	NULL
immune	NULL
system	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Apoptosis	NULL
,	NULL
or	NULL
the	NULL
lack	NULL
of	NULL
apoptosis	NULL
,	NULL
contributes	NULL
to	NULL
the	NULL
pathogenesis	NULL
of	NULL
a	NULL
number	NULL
of	NULL
diseases	NULL
,	NULL
including	NULL
viral	NULL
infection	NULL
,	NULL
autoimmune	NULL
disease	NULL
,	NULL
and	NULL
,	NULL
in	NULL
partic-ular	NULL
,	NULL
cancer	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

In	NULL
the	NULL
latter	NULL
context	NULL
,	NULL
evidence	NULL
has	NULL
been	NULL
accumulating	NULL
that	NULL
oncogenesis	NULL
requires	NULL
an	NULL
antiapoptotic	NULL
function	NULL
that	NULL
protects	NULL
transformed	NULL
cells	NULL
from	NULL
programmed	NULL
cell	NULL
death	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
which	NULL
regulates	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
diverse	NULL
set	NULL
of	NULL
genes	NULL
involved	NULL
in	NULL
immune	NULL
function	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
proliferation	NULL
(	NULL
21	NULL
)	NULL
,	NULL
also	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
contribute	NULL
to	NULL
cell	NULL
survival	NULL
by	NULL
conveying	NULL
protection	NULL
against	NULL
cell	NULL
death	NULL
,	NULL
induced	NULL
by	NULL
a	NULL
range	NULL
of	NULL
different	NULL
apoptotic	NULL
stimuli	NULL
(	NULL
22-28	NULL
)	NULL
.	NULL

It	NULL
recently	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
this	NULL
protection	NULL
is	NULL
conveyed	NULL
by	NULL
the	NULL
induction	NULL
of	NULL
genes	NULL
that	NULL
encode	NULL
different	NULL
inhibitor	NULL
of	NULL
apoptosis	NULL
proteins	NULL
(	NULL
29-32	NULL
)	NULL
,	NULL
which	NULL
inhibit	NULL
members	NULL
of	NULL
the	NULL
caspase	NULL
family	NULL
of	NULL
cell-death	NULL
proteases	NULL
(	NULL
33	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
is	NULL
regulated	NULL
by	NULL
cytoplasmic	NULL
inhibitor	NULL
proteins	NULL
,	NULL
IxBs	NULL
,	NULL
which	NULL
sequester	NULL
NF-KB	NULL
in	NULL
the	NULL
cytoplasm	NULL
,	NULL
preventing	NULL
its	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
and	NULL
induction	NULL
of	NULL
«	NULL
B-dependent	NULL
gene	NULL
expression	NULL
.	NULL

Signal-induced	NULL
phosphorylation	NULL
of	NULL
IxB	NULL
by	NULL
IxB	NULL
kinases	NULL
(	NULL
reviewed	NULL
in	NULL
ref	NULL
.	NULL

34	NULL
)	NULL
targets	NULL
IxB	NULL
to	NULL
a	NULL
proteasomal	NULL
degradation	NULL
pathway	NULL
,	NULL
resulting	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
release	NULL
,	NULL
nuclear	NULL
translocation	NULL
,	NULL
and	NULL
activation	NULL
.	NULL

In	NULL
earlier	NULL
work	NULL
,	NULL
it	NULL
was	NULL
demonstrated	NULL
that	NULL
transformation	NULL
of	NULL
T.	NULL
paerva-infected	NULL
T	NULL
cells	NULL
is	NULL
accompanied	NULL
by	NULL
high	NULL
levels	NULL
of	NULL
NF-KB	NULL
in	NULL
the	NULL
nucleus	NULL
(	NULL
35	NULL
)	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
it	NULL
was	NULL
shown	NULL
that	NULL
this	NULL
transformation	NULL
involves	NULL
continuous	NULL
parasite-dependent	NULL
degradation	NULL
of	NULL
IxB	NULL
,	NULL
resulting	NULL
in	NULL
constitutive	NULL
nuclear	NULL
translocation	NULL
and	NULL
transcriptional	NULL
activity	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Upon	NULL
elimination	NULL
of	NULL
the	NULL
parasite	NULL
,	NULL
IxB	NULL
degradation	NULL
and	NULL
NF-KB	NULL
nuclear	NULL
translocation	NULL
are	NULL
down-regulated	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
NF-	NULL
«	NULL
B-responsive	NULL
genes	NULL
such	NULL
as	NULL
the	NULL
IL-2	NULL
and	NULL
IL-2R	NULL
genes	NULL
(	NULL
5	NULL
,	NULL
37-39	NULL
)	NULL
is	NULL
arrested	NULL
.	NULL

Given	NULL
that	NULL
oncogenesis	NULL
in	NULL
tumor	NULL
cells	NULL
requires	NULL
a	NULL
functional	NULL
antiapoptotic	NULL
mechanism	NULL
(	NULL
18	NULL
,	NULL
19	NULL
,	NULL
40-42	NULL
)	NULL
and	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
suppress	NULL
apoptosis	NULL
induced	NULL
by	NULL
a	NULL
range	NULL
of	NULL
stimuli	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
specific	NULL
role	NULL
of	NULL
parasite-induced	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
the	NULL
survival	NULL
of	NULL
T.	NULL
parva-transformed	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
demonstrate	NULL
that	NULL
a	NULL
stimulus	NULL
to	NULL
undergo	NULL
spontaneous	NULL
apoptosis	NULL
is	NULL
activated	NULL
in	NULL
7.	NULL
parva-transformed	NULL
T	NULL
cells	NULL
that	NULL
is	NULL
blocked	NULL
,	NULL
however	NULL
,	NULL
by	NULL
activated	NULL
NF-KB	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
inducing	NULL
the	NULL
expression	NULL
of	NULL
genes	NULL
that	NULL
contribute	NULL
to	NULL
proliferation	NULL
(	NULL
5	NULL
,	NULL
37-39	NULL
)	NULL
,	NULL
permanently	NULL
activated	NULL
NF-B	NULL
is	NULL
also	NULL
critically	NULL
required	NULL
for	NULL
the	NULL
survival	NULL
of	NULL
T.	NULL
parva-transformed	NULL
T	NULL
cells	NULL
.	NULL

Abbreviations	NULL
:	NULL
TPCK	NULL
,	NULL
N-	NULL
«	NULL
-tosyl-L-phenylalanine	NULL
chloromethyl	NULL
ke-	NULL
tone	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
;	NULL
GFP	NULL
,	NULL
green	NULL
fluores-	NULL
cent	NULL
protein	NULL
.	NULL

To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
at	NULL
:	NULL
Institute	NULL
of	NULL
Animal	NULL
Pathology	NULL
,	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Pathology	NULL
,	NULL
Linggassstrasse	NULL
122	NULL
,	NULL
CH-3012	NULL
Berne	NULL
,	NULL
Switzerland	NULL
.	NULL

e-mail	NULL
:	NULL
dirk.dobbelaere	NULL
@	NULL
itpa.unibe.ch	NULL
.	NULL

Cell	NULL
Biology	NULL
:	NULL
Heussler	NULL
et	NULL
al	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
Culture	NULL
.	NULL

7.	NULL
parva-infected	NULL
T	NULL
cells	NULL
(	NULL
5	NULL
)	NULL
were	NULL
cultured	NULL
at	NULL
37°C	NULL
in	NULL
Leibovitz	NULL
L15	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
heat-inactivated	NULL
FBS	NULL
,	NULL
20	NULL
mM	NULL
Hepes	NULL
(	NULL
pH	NULL
7.1	NULL
)	NULL
,	NULL
L-glutamine	NULL
(	NULL
2	NULL
mM	NULL
)	NULL
,	NULL
benzylpenicillin	NULL
(	NULL
100	NULL
units	NULL
ml~	NULL
'	NULL
)	NULL
,	NULL
and	NULL
streptomycin	NULL
sulfate	NULL
(	NULL
100	NULL
ugml~	NULL
'	NULL
)	NULL
(	NULL
cL15	NULL
)	NULL
.	NULL

Chemical	NULL
inhibitors	NULL
were	NULL
added	NULL
to	NULL
the	NULL
final	NULL
concentrations	NULL
as	NULL
follows	NULL
:	NULL
N-a-tosyl-L-phenylala-nine	NULL
chloromethyl	NULL
ketone	NULL
(	NULL
TPCK	NULL
,	NULL
25	NULL
mM	NULL
;	NULL
Sigma	NULL
)	NULL
,	NULL
BAY	NULL
11-7082	NULL
(	NULL
50	NULL
wM	NULL
;	NULL
Calbiochem	NULL
)	NULL
or	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
text	NULL
.	NULL

Plasmids	NULL
:	NULL
Construction	NULL
of	NULL
peDNA3-I*	NULL
>	NULL
``	NULL
4	NULL
and	NULL
p6SAC	NULL
.	NULL

The	NULL
peDNA3-IS	NULL
>	NULL
24	NULL
construct	NULL
was	NULL
prepared	NULL
by	NULL
subcloning	NULL
the	NULL
cDNA	NULL
fragment	NULL
isolated	NULL
from	NULL
(	NULL
43	NULL
)	NULL
into	NULL
the	NULL
HindIII	NULL
and	NULL
BamHI	NULL
sites	NULL
of	NULL
pecDNA3	NULL
(	NULL
Invitrogen	NULL
)	NULL
.	NULL

The	NULL
p6SAC	NULL
deletion	NULL
mutant	NULL
corresponding	NULL
to	NULL
bp	NULL
1-1248	NULL
of	NULL
murine	NULL
p65	NULL
cDNA	NULL
was	NULL
generated	NULL
by	NULL
reverse	NULL
transcription-PCR	NULL
and	NULL
sub-cloned	NULL
into	NULL
peDNA3	NULL
to	NULL
generate	NULL
peDNA¥A3-p65SAC	NULL
.	NULL

pCMV-GFPsg25	NULL
was	NULL
a	NULL
kind	NULL
gift	NULL
of	NULL
G.	NULL
Pavlakis	NULL
,	NULL
(	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Frederick	NULL
Cancer	NULL
Research	NULL
and	NULL
Development	NULL
Cen-ter	NULL
,	NULL
Frederick	NULL
,	NULL
MD	NULL
)	NULL
and	NULL
has	NULL
been	NULL
described	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Apoptosis	NULL
Assay	NULL
.	NULL

T.	NULL
parva	NULL
cells	NULL
were	NULL
cultured	NULL
at	NULL
2	NULL
%	NULL
10°	NULL
cells	NULL
ml~	NULL
'	NULL
in	NULL
cL15	NULL
for	NULL
5	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
drugs	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
by	NULL
centrifugation	NULL
and	NULL
washed	NULL
in	NULL
cold	NULL
PBS	NULL
.	NULL

After	NULL
centrifugation	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
cold	NULL
staining	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
Hepes/140	NULL
mM	NULL
NaCl/5	NULL
mM	NULL
CaC	NULL
]	NULL
;	NULL
)	NULL
.	NULL

Staining	NULL
with	NULL
recombinant	NULL
annexin-V-FITC	NULL
and	NULL
propidiumi-odide	NULL
was	NULL
done	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
using	NULL
standard	NULL
protocols	NULL
and	NULL
a	NULL
FACScan	NULL
using	NULL
LYSYSII	NULL
software	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

Cell	NULL
Lysates	NULL
and	NULL
Immunoblot	NULL
Analysis	NULL
.	NULL

Cells	NULL
were	NULL
collected	NULL
and	NULL
washed	NULL
twice	NULL
in	NULL
ice-cold	NULL
PBS	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
and	NULL
then	NULL
processed	NULL
for	NULL
immunoblot	NULL
analysis	NULL
as	NULL
described	NULL
(	NULL
36	NULL
)	NULL
.	NULL

A	NULL
rabbit	NULL
antipeptide	NULL
polyclonal	NULL
Ab	NULL
with	NULL
the	NULL
following	NULL
specificity	NULL
was	NULL
used	NULL
:	NULL
IxBa	NULL
(	NULL
C-terminal	NULL
21	NULL
amino	NULL
acids	NULL
;	NULL
sc-371	NULL
,	NULL
Santa	NULL
Cruz	NULL
Biotechnolo-gy	NULL
)	NULL
.	NULL

Bound	NULL
primary	NULL
Ab	NULL
was	NULL
detected	NULL
by	NULL
using	NULL
horseradish	NULL
peroxidase-conjugated	NULL
goat	NULL
anti-rabbit	NULL
IgG	NULL
and	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
ECL	NULL
,	NULL
Amersham	NULL
Pharmacia	NULL
)	NULL
.	NULL

Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assay	NULL
(	NULL
EMSA	NULL
)	NULL
,	NULL
Cell	NULL
Trans-fection	NULL
,	NULL
and	NULL
Chloramphenicol	NULL
Acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
As-says	NULL
.	NULL

EMSA	NULL
was	NULL
carried	NULL
out	NULL
as	NULL
described	NULL
in	NULL
standard	NULL
protocols	NULL
(	NULL
35	NULL
)	NULL
using	NULL
oligonucleotides	NULL
(	NULL
5'-GAGGGGACTTTCCG-3	NULL
'	NULL
and	NULL
its	NULL
complement	NULL
)	NULL
in	NULL
which	NULL
the	NULL
consensus	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
site	NULL
is	NULL
incorporated	NULL
.	NULL

Before	NULL
preparation	NULL
of	NULL
nuclear	NULL
extracts	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
25	NULL
uM	NULL
TPCK	NULL
for	NULL
1	NULL
,	NULL
2	NULL
,	NULL
3	NULL
,	NULL
4	NULL
,	NULL
or	NULL
5	NULL
h.	NULL
Plasmids	NULL
used	NULL
for	NULL
transfection	NULL
have	NULL
been	NULL
described	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Plasmid	NULL
-121/+232	NULL
HIV-CAT	NULL
(	NULL
abbreviated	NULL
HIV-CAT	NULL
)	NULL
was	NULL
derived	NULL
by	NULL
modification	NULL
of	NULL
pBLCATS	NULL
containing	NULL
the	NULL
bacterial	NULL
CAT	NULL
gene	NULL
.	NULL

In	NULL
HIV-CAT	NULL
,	NULL
the	NULL
CAT	NULL
gene	NULL
is	NULL
under	NULL
control	NULL
of	NULL
an	NULL
HIV-1	NULL
enhancer	NULL
with	NULL
two	NULL
«	NULL
B	NULL
elements	NULL
and	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
the	NULL
enhancer	NULL
.	NULL

Cells	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
using	NULL
standard	NULL
protocols	NULL
(	NULL
2	NULL
X	NULL
10	NULL
``	NULL
cells	NULL
ml-	NULL
'	NULL
,	NULL
600-pl	NULL
aliquots	NULL
,	NULL
50	NULL
ug	NULL
of	NULL
plasmid	NULL
DNA	NULL
,	NULL
430	NULL
V	NULL
,	NULL
250	NULL
uF	NULL
)	NULL
.	NULL

For	NULL
cotransfection	NULL
experiments	NULL
10	NULL
ug	NULL
of	NULL
HIV-CAT	NULL
and	NULL
40	NULL
pg	NULL
of	NULL
the	NULL
expression	NULL
plasmids	NULL
(	NULL
pcDNA3-I°	NULL
>	NULL
>	NULL
4~	NULL
and	NULL
p65SAC	NULL
)	NULL
were	NULL
used	NULL
.	NULL

After	NULL
electroporation	NULL
,	NULL
cells	NULL
were	NULL
placed	NULL
on	NULL
ice	NULL
for	NULL
5	NULL
min	NULL
and	NULL
then	NULL
diluted	NULL
in	NULL
Leibovitz	NULL
L15	NULL
medium	NULL
and	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
12	NULL
h	NULL
,	NULL
collected	NULL
and	NULL
washed	NULL
with	NULL
PBS	NULL
,	NULL
and	NULL
then	NULL
lysed	NULL
by	NULL
freeze-thawing	NULL
in	NULL
a	NULL
CAT	NULL
assay	NULL
buffer	NULL
(	NULL
100	NULL
mM	NULL
Tris	NULL
,	NULL
pH	NULL
7.4/1	NULL
mM	NULL
EDTA/1	NULL
mM	NULL
DTT	NULL
)	NULL
.	NULL

After	NULL
centrifugation	NULL
,	NULL
the	NULL
superna-tant	NULL
was	NULL
collected	NULL
,	NULL
incubated	NULL
for	NULL
6	NULL
min	NULL
at	NULL
65°C	NULL
,	NULL
then	NULL
recen-trifuged	NULL
.	NULL

A	NULL
15-pl	NULL
aliquot	NULL
was	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
by	NULL
using	NULL
9.25	NULL
x	NULL
10°	NULL
Bq	NULL
(	NULL
250	NULL
nCi	NULL
)	NULL
of	NULL
[	NULL
'	NULL
!	NULL

*C	NULL
]	NULL
-chloramphenicol	NULL
in	NULL
CAT	NULL
assay	NULL
buffer	NULL
supplemented	NULL
with	NULL
100	NULL
pg	NULL
BSA	NULL
and	NULL
2	NULL
mg/ml	NULL
n-butyryl	NULL
CoA	NULL
.	NULL

Butyrylated	NULL
chloramphenicol	NULL
was	NULL
extracted	NULL
by	NULL
using	NULL
xylene	NULL
,	NULL
and	NULL
activity	NULL
was	NULL
determined	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
.	NULL

Green	NULL
Fluorescent	NULL
Protein	NULL
(	NULL
GFP	NULL
)	NULL
Expression	NULL
Assay	NULL
.	NULL

7.	NULL
parva-transformed	NULL
T	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
with	NULL
50	NULL
ug	NULL
of	NULL
pCMV-GFPsg25	NULL
(	NULL
44	NULL
)	NULL
as	NULL
described	NULL
above	NULL
and	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
7313	NULL
A	NULL
TPCK	NULL
IxBo	NULL
.	NULL

*E	NULL
«	NULL
am	NULL
:	NULL
Game	NULL
guar	NULL
rine	NULL
»	NULL
@	NULL
i-	NULL
pir	NULL
BAY	NULL
11-7082	NULL
IcB	NULL
@	NULL
``	NULL
*F	NULL
|	NULL
&	NULL
M	NULL
%	NULL
qu	NULL
»	NULL
ess	NULL
cus	NULL
cue	NULL
min	NULL
0	NULL
15	NULL
30	NULL
45	NULL
60	NULL
100	NULL
:	NULL
oy	NULL
L	NULL
-	NULL
o	NULL
-	NULL
co	NULL
o	NULL
-	NULL
_o	NULL
oJ	NULL
CAT	NULL
activity	NULL
(	NULL
%	NULL
)	NULL
I	NULL
b	NULL
=	NULL
]	NULL
st	NULL
-	NULL
+	NULL
P	NULL
Meee	NULL
4	NULL
m	NULL
control	NULL
TPCK	NULL
TPCK	NULL
TPCK	NULL
1uM	NULL
5uM	NULL
10uM	NULL
80	NULL
O	NULL
70	NULL
Bay	NULL
11-7082	NULL
aps	NULL
control	NULL
TPCK	NULL
relative	NULL
cell	NULL
number	NULL
10	NULL
102	NULL
103	NULL
104	NULL
annexin-V-FITC	NULL
binding	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

The	NULL
inhibitors	NULL
of	NULL
IxB	NULL
phosphorylation	NULL
TPCK	NULL
and	NULL
BAY	NULL
11-7082	NULL
block	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
and	NULL
induce	NULL
apoptosis	NULL
in	NULL
T.	NULL
parve-transformed	NULL
T	NULL
cells	NULL
.	NULL

(	NULL
4	NULL
)	NULL
TPCK	NULL
and	NULL
BAY	NULL
11-7082	NULL
inhibit	NULL
IxBa	NULL
phosphorylation	NULL
Whole-cell	NULL
protein	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
TPCK	NULL
(	NULL
25	NULL
uM	NULL
)	NULL
or	NULL
BAY	NULL
11-7082	NULL
(	NULL
50	NULL
wM	NULL
)	NULL
for	NULL
different	NULL
lengths	NULL
of	NULL
time	NULL
,	NULL
and	NULL
immunoblot	NULL
analysis	NULL
was	NULL
carried	NULL
out	NULL
by	NULL
using	NULL
anti-IxBa	NULL
antibodies	NULL
.	NULL

(	NULL
B	NULL
)	NULL
T.	NULL
parva-transformed	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
-121/+232	NULL
HIV-CAT	NULL
construct	NULL
and	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
TPCK	NULL
and	NULL
CAT	NULL
activity	NULL
determined	NULL
after	NULL
16	NULL
h.	NULL
Error	NULL
bars	NULL
represent	NULL
the	NULL
SD	NULL
for	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Log-arithmically	NULL
growing	NULL
T.	NULL
parve-infected	NULL
T	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
TPCK	NULL
(	NULL
25	NULL
wM	NULL
)	NULL
or	NULL
BAY	NULL
11-7082	NULL
(	NULL
50	NULL
wM	NULL
)	NULL
for	NULL
5	NULL
h	NULL
,	NULL
and	NULL
annexin-V-FITC	NULL
binding	NULL
was	NULL
analyzed	NULL
by	NULL
FACScan	NULL
.	NULL

cultured	NULL
for	NULL
2	NULL
h	NULL
in	NULL
complete	NULL
L15	NULL
medium	NULL
containing	NULL
FCS	NULL
.	NULL

TPCK	NULL
(	NULL
1	NULL
mM	NULL
,	NULL
10	NULL
uM	NULL
,	NULL
25	NULL
uM	NULL
)	NULL
then	NULL
was	NULL
added	NULL
for	NULL
5	NULL
h	NULL
and	NULL
the	NULL
number	NULL
of	NULL
GFP-expressing	NULL
cells	NULL
was	NULL
counted	NULL
by	NULL
using	NULL
a	NULL
Neubauer	NULL
chamber	NULL
and	NULL
immunofluorescence	NULL
microscopy	NULL
(	NULL
X	NULL
40	NULL
magnification	NULL
)	NULL
.	NULL

For	NULL
cotransfection	NULL
experiments	NULL
10	NULL
ug	NULL
of	NULL
7314	NULL
Cell	NULL
Biology	NULL
:	NULL
Heussler	NULL
et	NULL
al	NULL
.	NULL

pCMV-GFPsg25	NULL
and	NULL
40	NULL
pg	NULL
of	NULL
the	NULL
expression	NULL
plasmids	NULL
and	NULL
p65SAC	NULL
)	NULL
were	NULL
used	NULL
.	NULL

RESULTS	NULL
Inhibitors	NULL
of	NULL
IxBa	NULL
Phosphorylation	NULL
Induce	NULL
Apoptosis	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
would	NULL
initiate	NULL
a	NULL
cell	NULL
death	NULL
response	NULL
,	NULL
T.	NULL
parva-transformed	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
two	NULL
potent	NULL
inhibitors	NULL
of	NULL
the	NULL
NF-kB	NULL
activation	NULL
pathway	NULL
.	NULL

TPCK	NULL
(	NULL
45	NULL
,	NULL
46	NULL
)	NULL
and	NULL
BAY	NULL
11-7082	NULL
(	NULL
47	NULL
)	NULL
are	NULL
unrelated	NULL
compounds	NULL
that	NULL
both	NULL
inhibit	NULL
IxBa	NULL
phosphorylation	NULL
and	NULL
subsequent	NULL
degradation	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
IxBa	NULL
revealed	NULL
that	NULL
treatment	NULL
of	NULL
T.	NULL
parva-infected	NULL
T	NULL
cells	NULL
with	NULL
either	NULL
compound	NULL
resulted	NULL
in	NULL
a	NULL
rapid	NULL
block	NULL
in	NULL
I	NULL
«	NULL
xBa	NULL
phosphorylation	NULL
as	NULL
judged	NULL
by	NULL
the	NULL
disappearance	NULL
of	NULL
the	NULL
phosphorylated	NULL
form	NULL
of	NULL
I	NULL
«	NULL
Ba	NULL
,	NULL
which	NULL
migrates	NULL
with	NULL
reduced	NULL
electrophoretic	NULL
mobility	NULL
in	NULL
SDS/PAGE	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
,	NULL
black	NULL
arrowhead	NULL
)	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
phosphorylated	NULL
IxBa	NULL
formation	NULL
was	NULL
most	NULL
pronounced	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
BAY	NULL
11-7082	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
blocking	NULL
IxBa	NULL
phosphorylation	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activity	NULL
also	NULL
was	NULL
tested	NULL
.	NULL

Treatment	NULL
of	NULL
7.	NULL
parva-transformed	NULL
T	NULL
cells	NULL
with	NULL
TPCK	NULL
was	NULL
accompanied	NULL
by	NULL
a	NULL
dose-dependent	NULL
arrest	NULL
of	NULL
«	NULL
B-dependent	NULL
HIV-CAT	NULL
reporter	NULL
gene	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

To	NULL
see	NULL
whether	NULL
TPCK	NULL
or	NULL
BAY	NULL
11-7082	NULL
were	NULL
capable	NULL
of	NULL
inducing	NULL
apoptosis	NULL
,	NULL
T.	NULL
parva-transformed	NULL
T	NULL
cells	NULL
were	NULL
analyzed	NULL
by	NULL
using	NULL
an	NULL
annexin-V	NULL
binding	NULL
assay	NULL
.	NULL

Annexin-V	NULL
binds	NULL
phos-phatidylserine	NULL
,	NULL
which	NULL
normally	NULL
is	NULL
situated	NULL
on	NULL
the	NULL
inner	NULL
leaflet	NULL
of	NULL
the	NULL
plasma	NULL
membrane	NULL
,	NULL
but	NULL
translocates	NULL
to	NULL
the	NULL
outer	NULL
layer	NULL
of	NULL
the	NULL
membrane	NULL
(	NULL
cell	NULL
surface	NULL
)	NULL
during	NULL
the	NULL
early	NULL
phases	NULL
of	NULL
apoptosis	NULL
,	NULL
at	NULL
a	NULL
time	NULL
when	NULL
the	NULL
cell	NULL
membrane	NULL
itself	NULL
is	NULL
still	NULL
intact	NULL
(	NULL
48	NULL
,	NULL
49	NULL
)	NULL
.	NULL

Flow-cytometric	NULL
analysis	NULL
showed	NULL
that	NULL
most	NULL
cells	NULL
bound	NULL
FITC-labeled	NULL
annexin	NULL
V	NULL
on	NULL
exposure	NULL
to	NULL
either	NULL
TPCK	NULL
or	NULL
BAY	NULL
11-7082	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
,	NULL
with	NULL
BAY	NULL
11-7082	NULL
being	NULL
the	NULL
strongest	NULL
inducer	NULL
of	NULL
phosphatidylserine	NULL
surface	NULL
expression	NULL
.	NULL

Treated	NULL
cells	NULL
also	NULL
showed	NULL
the	NULL
typical	NULL
morphological	NULL
hallmarks	NULL
of	NULL
apoptosis	NULL
,	NULL
including	NULL
cell	NULL
shrinkage	NULL
,	NULL
membrane	NULL
blebbing	NULL
,	NULL
and	NULL
nuclear	NULL
condensation	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

NF-xB	NULL
.	NULL

Say	NULL
120	NULL
80	NULL
g	NULL
C	NULL
w	NULL
®	NULL
100f	NULL
3	NULL
0	NULL
§	NULL
ss	NULL
§	NULL
6	NULL
£	NULL
D	NULL
€	NULL
60	NULL
o	NULL
C	NULL
t	NULL
f=	NULL
i	NULL
8	NULL
as	NULL
i	NULL
m	NULL
*°	NULL
y	NULL
2	NULL
&	NULL
&	NULL
20+	NULL
3	NULL
5	NULL
a	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
NF-kB	NULL
DNA	NULL
binding	NULL
activity	NULL
correlates	NULL
with	NULL
the	NULL
induction	NULL
of	NULL
apoptosis	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
TPCK	NULL
(	NULL
25	NULL
uM	NULL
)	NULL
for	NULL
different	NULL
times	NULL
as	NULL
indicated	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
complexes	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
were	NULL
demonstrated	NULL
by	NULL
electrophoretic	NULL
mobility-shift	NULL
assay	NULL
(	NULL
Upper	NULL
)	NULL
and	NULL
quantitated	NULL
by	NULL
PhosphorImager	NULL
analysis	NULL
(	NULL
Lower	NULL
,	NULL
gray	NULL
bars	NULL
)	NULL
.	NULL

Cells	NULL
also	NULL
were	NULL
analyzed	NULL
by	NULL
FACScan	NULL
,	NULL
and	NULL
the	NULL
percentage	NULL
of	NULL
annexin-V-FITC	NULL
binding	NULL
cells	NULL
were	NULL
determined	NULL
at	NULL
each	NULL
time	NULL
point	NULL
(	NULL
Lower	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
100	NULL
q	NULL
zo	NULL
80	NULL
-~	NULL
a	NULL
g	NULL
40	NULL
(	NULL
_	NULL
|	NULL
<	NULL
C	NULL
o	NULL
20	NULL
-	NULL
{	NULL
18	NULL
0	NULL
|	NULL
mene	NULL
pCDNA3	NULL
-	NULL
pCDNA3-	NULL
_	NULL
pCMV	NULL
__	NULL
pCMV-control	NULL
18324	NULL
control	NULL
peSAC	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Dominant	NULL
negative	NULL
mutant	NULL
forms	NULL
of	NULL
IxBa	NULL
and	NULL
p65	NULL
inhibit	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activity	NULL
in	NULL
T.	NULL
perve-transformed	NULL
T	NULL
cells	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
monitored	NULL
in	NULL
cells	NULL
that	NULL
were	NULL
cotransfected	NULL
with	NULL
-121/	NULL
+232	NULL
HIV-CAT	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
and	NULL
either	NULL
the	NULL
empty	NULL
expression	NULL
vectors	NULL
pcDNA3	NULL
and	NULL
pCMV	NULL
,	NULL
or	NULL
the	NULL
expression	NULL
vectors	NULL
pecDNA3-I°	NULL
>	NULL
24	NULL
or	NULL
pCMV-p65AC	NULL
(	NULL
40	NULL
ug	NULL
each	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
presented	NULL
as	NULL
percentage	NULL
of	NULL
CAT	NULL
activity	NULL
measured	NULL
for	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
corresponding	NULL
control	NULL
plasmid	NULL
constructs	NULL
.	NULL

Error	NULL
bars	NULL
represent	NULL
the	NULL
SD	NULL
for	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Blocking	NULL
NF-KB	NULL
Activation	NULL
Reveals	NULL
a	NULL
Temporal	NULL
Relationship	NULL
with	NULL
the	NULL
Induction	NULL
of	NULL
Apoptosis	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
a	NULL
correlation	NULL
exists	NULL
between	NULL
the	NULL
occurrence	NULL
of	NULL
apoptosis	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
inhibition	NULL
,	NULL
a	NULL
time-course	NULL
experiment	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
which	NULL
the	NULL
effect	NULL
of	NULL
TPCK	NULL
on	NULL
NF-kB	NULL
DNA	NULL
binding	NULL
activity	NULL
,	NULL
measured	NULL
in	NULL
a	NULL
quantitative	NULL
electrophoretic	NULL
mobility-shift	NULL
assay	NULL
,	NULL
and	NULL
annexin	NULL
V-FITC	NULL
binding	NULL
was	NULL
monitored	NULL
over	NULL
a	NULL
period	NULL
of	NULL
5	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

The	NULL
block	NULL
of	NULL
IxBa	NULL
phosphorylation	NULL
induced	NULL
by	NULL
TPCK	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
,	NULL
which	NULL
became	NULL
apparent	NULL
within	NULL
30	NULL
min	NULL
and	NULL
was	NULL
complete	NULL
within	NULL
45	NULL
min	NULL
,	NULL
was	NULL
accompanied	NULL
by	NULL
the	NULL
arrest	NULL
of	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

The	NULL
latter	NULL
could	NULL
be	NULL
observed	NULL
within	NULL
1	NULL
h	NULL
of	NULL
treatment	NULL
and	NULL
was	NULL
almost	NULL
complete	NULL
within	NULL
2	NULL
h.	NULL
The	NULL
decrease	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
activity	NULL
,	NULL
in	NULL
turn	NULL
,	NULL
immediately	NULL
preceded	NULL
the	NULL
onset	NULL
of	NULL
apoptosis	NULL
,	NULL
with	NULL
the	NULL
first	NULL
annexin	NULL
V-FITC	NULL
binding	NULL
cells	NULL
being	NULL
detectable	NULL
at	NULL
2	NULL
h	NULL
,	NULL
steadily	NULL
increasing	NULL
to	NULL
a	NULL
maximum	NULL
at	NULL
5	NULL
h.	NULL
This	NULL
observation	NULL
shows	NULL
that	NULL
TPCK-mediated	NULL
inhibition	NULL
of	NULL
NF-kB	NULL
correlates	NULL
closely	NULL
with	NULL
the	NULL
induction	NULL
of	NULL
apoptosis	NULL
.	NULL

1004	NULL
C	NULL
&	NULL
so	NULL
|	NULL
»	NULL
E	NULL
S	NULL
,	NULL
60	NULL
C	NULL
14	NULL
6	NULL
40	NULL
a	NULL
$	NULL
20	NULL
it	NULL
t	NULL
(	NULL
)	NULL
4	NULL
;	NULL
;	NULL
-_¢	NULL
control	NULL
TPCK	NULL
TPCK	NULL
TPCK	NULL
1	NULL
uM	NULL
10	NULL
uM	NULL
25	NULL
uM	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

-	NULL
Analysis	NULL
of	NULL
GFP	NULL
expression	NULL
in	NULL
7.	NULL
parva-transformed	NULL
T	NULL
cells	NULL
undergoing	NULL
apoptosis	NULL
.	NULL

Cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
plasmid	NULL
pCMV-GFPsg25	NULL
(	NULL
50	NULL
ug	NULL
)	NULL
and	NULL
treated	NULL
for	NULL
5	NULL
h	NULL
with	NULL
TPCK	NULL
as	NULL
indicated	NULL
.	NULL

GFP	NULL
expression	NULL
was	NULL
monitored	NULL
in	NULL
a	NULL
counting	NULL
chamber	NULL
by	NULL
using	NULL
a	NULL
fluorescence	NULL
microscope	NULL
.	NULL

Error	NULL
bars	NULL
represent	NULL
the	NULL
SD	NULL
for	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Cell	NULL
Biology	NULL
:	NULL
Heussler	NULL
et	NULL
al	NULL
.	NULL

Similarly	NULL
,	NULL
the	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
by	NULL
BAY	NULL
11-7082	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
induction	NULL
of	NULL
apoptosis	NULL
by	NULL
BAY	NULL
11-7082	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
were	NULL
preceded	NULL
by	NULL
a	NULL
block	NULL
in	NULL
IxBa	NULL
phosphorylation	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
,	NULL
Lower	NULL
)	NULL
.	NULL

Direct	NULL
Interference	NULL
with	NULL
Components	NULL
of	NULL
the	NULL
NF-xB	NULL
Activation	NULL
Pathway	NULL
Induces	NULL
Apoptosis	NULL
.	NULL

Despite	NULL
the	NULL
fact	NULL
that	NULL
TPCK-induced	NULL
and	NULL
BAY	NULL
11-7082-induced	NULL
apoptosis	NULL
correlated	NULL
closely	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
inhibition	NULL
,	NULL
it	NULL
could	NULL
not	NULL
be	NULL
completely	NULL
excluded	NULL
that	NULL
these	NULL
inhibitors	NULL
induce	NULL
apoptosis	NULL
by	NULL
affecting	NULL
other	NULL
signaling	NULL
pathways	NULL
that	NULL
are	NULL
essential	NULL
for	NULL
maintaining	NULL
cell	NULL
survival	NULL
.	NULL

To	NULL
confirm	NULL
the	NULL
antiapoptotic	NULL
role	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
T.	NULL
parva-transformed	NULL
T	NULL
cells	NULL
in	NULL
a	NULL
direct	NULL
manner	NULL
,	NULL
we	NULL
designed	NULL
A	NULL
peDNA	NULL
100	NULL
co	NULL
O	NULL
WD	NULL
-	NULL
$	NULL
O	NULL
_	NULL
G	NULL
GFP-expressing	NULL
cells	NULL
(	NULL
%	NULL
)	NULL
a	NULL
3	NULL
D	NULL
nr	NULL
pCDNA3	NULL
pCDNAs-control	NULL
(	NULL
832A	NULL
&	NULL
control	NULL
pCMV	NULL
_	NULL
pCMV-peSAc	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
7315	NULL
transfection	NULL
experiments	NULL
aimed	NULL
at	NULL
interfering	NULL
directly	NULL
with	NULL
specific	NULL
components	NULL
of	NULL
the	NULL
NF-KB	NULL
activation	NULL
pathway	NULL
through	NULL
the	NULL
expression	NULL
of	NULL
dominant	NULL
negative	NULL
mutants	NULL
.	NULL

We	NULL
used	NULL
a	NULL
repressor	NULL
form	NULL
of	NULL
I	NULL
«	NULL
Ba	NULL
,	NULL
which	NULL
contains	NULL
a	NULL
serine-to-alanine	NULL
mutation	NULL
at	NULL
residue	NULL
32	NULL
(	NULL
IxBaS32A	NULL
)	NULL
(	NULL
43	NULL
)	NULL
.	NULL

This	NULL
mutation	NULL
prevents	NULL
IxBa	NULL
phosphorylation	NULL
by	NULL
IxB	NULL
kinase	NULL
and	NULL
subsequent	NULL
proteasomal	NULL
degradation	NULL
(	NULL
50	NULL
,	NULL
51	NULL
)	NULL
,	NULL
impeding	NULL
both	NULL
NF-kB	NULL
nuclear	NULL
translocation	NULL
and	NULL
DNA	NULL
binding	NULL
.	NULL

In	NULL
a	NULL
second	NULL
approach	NULL
,	NULL
a	NULL
dominant	NULL
negative	NULL
mutant	NULL
form	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
subunit	NULL
p65	NULL
lacking	NULL
the	NULL
transcriptional	NULL
activation	NULL
domain	NULL
[	NULL
p65	NULL
(	NULL
A	NULL
)	NULL
C	NULL
]	NULL
was	NULL
used	NULL
to	NULL
inhibit	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activity	NULL
.	NULL

Transient	NULL
expression	NULL
of	NULL
IxBaS32A	NULL
and	NULL
p65	NULL
(	NULL
A	NULL
)	NULL
C	NULL
in	NULL
T.	NULL
[	NULL
892A	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Expression	NULL
of	NULL
IxBaS3ZA	NULL
or	NULL
p65	NULL
(	NULL
A	NULL
)	NULL
C	NULL
induces	NULL
apoptosis	NULL
in	NULL
7.	NULL
parve-transformed	NULL
T	NULL
cells	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Immunofluorescence	NULL
micrographs	NULL
(	NULL
final	NULL
magnification	NULL
X100	NULL
)	NULL
of	NULL
cells	NULL
cotransfected	NULL
with	NULL
pCMV-GFPsg25	NULL
and	NULL
either	NULL
the	NULL
empty	NULL
expression	NULL
vectors	NULL
pCDNA3	NULL
and	NULL
pCMV	NULL
,	NULL
or	NULL
vectors	NULL
expressing	NULL
IkBaS32A	NULL
or	NULL
p65	NULL
(	NULL
A	NULL
)	NULL
C.	NULL
(	NULL
B	NULL
)	NULL
Quantitation	NULL
of	NULL
GFP-expressing	NULL
cells	NULL
.	NULL

T.	NULL
parve-transformed	NULL
T	NULL
cells	NULL
were	NULL
transfected	NULL
as	NULL
described	NULL
above	NULL
,	NULL
and	NULL
the	NULL
number	NULL
of	NULL
cells	NULL
expressing	NULL
GFP	NULL
was	NULL
monitored	NULL
in	NULL
a	NULL
counting	NULL
chamber	NULL
by	NULL
using	NULL
a	NULL
fluorescence	NULL
microscope	NULL
.	NULL

Error	NULL
bars	NULL
represent	NULL
the	NULL
SD	NULL
for	NULL
three	NULL
separate	NULL
experiments	NULL
.	NULL

7316	NULL
Cell	NULL
Biology	NULL
:	NULL
Heussler	NULL
et	NULL
al	NULL
.	NULL

parva-transformed	NULL
T	NULL
cells	NULL
that	NULL
were	NULL
cotransfected	NULL
with	NULL
the	NULL
HIV-CAT	NULL
reporter	NULL
construct	NULL
caused	NULL
a	NULL
reduction	NULL
in	NULL
«	NULL
B-dependent	NULL
CAT	NULL
activity	NULL
of	NULL
80.3	NULL
%	NULL
and	NULL
58.7	NULL
%	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
,	NULL
demonstrating	NULL
that	NULL
both	NULL
constructs	NULL
effectively	NULL
reduced	NULL
NF-KB	NULL
transcriptional	NULL
activity	NULL
in	NULL
7.	NULL
parve-transformed	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
monitor	NULL
the	NULL
effects	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
inhibition	NULL
on	NULL
cell	NULL
viability	NULL
at	NULL
the	NULL
level	NULL
of	NULL
individual	NULL
cells	NULL
,	NULL
an	NULL
assay	NULL
system	NULL
first	NULL
had	NULL
to	NULL
be	NULL
established	NULL
that	NULL
allows	NULL
the	NULL
induction	NULL
of	NULL
apoptosis	NULL
T.	NULL
parva-transformed	NULL
T	NULL
cells	NULL
to	NULL
be	NULL
visualized	NULL
.	NULL

A	NULL
cell	NULL
viability	NULL
assay	NULL
,	NULL
developed	NULL
to	NULL
study	NULL
apoptosis	NULL
in	NULL
adherent	NULL
cells	NULL
and	NULL
which	NULL
relies	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
reporter	NULL
gene	NULL
by	NULL
viable	NULL
,	NULL
transiently	NULL
transfected	NULL
cells	NULL
(	NULL
20	NULL
,	NULL
52	NULL
,	NULL
53	NULL
)	NULL
,	NULL
was	NULL
adapted	NULL
for	NULL
T.	NULL
parve-transformed	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
assay	NULL
,	NULL
T.	NULL
parva-transformed	NULL
T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
pCMV-GFPsg25	NULL
expression	NULL
plasmid	NULL
(	NULL
44	NULL
)	NULL
and	NULL
the	NULL
number	NULL
of	NULL
cells	NULL
expressing	NULL
GFP	NULL
was	NULL
monitored	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
NF-KB	NULL
inhibition	NULL
.	NULL

Fig	NULL
.	NULL

4	NULL
demonstrates	NULL
how	NULL
upon	NULL
TPCK	NULL
treatment	NULL
the	NULL
number	NULL
of	NULL
7.	NULL
parva-transformed	NULL
T	NULL
cells	NULL
expressing	NULL
GFP	NULL
decreased	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
transient	NULL
expression	NULL
of	NULL
dominant	NULL
negative	NULL
mutants	NULL
that	NULL
block	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
also	NULL
affects	NULL
cell	NULL
viability	NULL
,	NULL
T.	NULL
parve-transformed	NULL
T	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
pCMV-GFPsg25	NULL
and	NULL
either	NULL
vectors	NULL
encoding	NULL
IkBaS3ZA	NULL
or	NULL
p65	NULL
(	NULL
A	NULL
)	NULL
C	NULL
,	NULL
or	NULL
the	NULL
corresponding	NULL
empty	NULL
expression	NULL
vectors	NULL
.	NULL

Expression	NULL
of	NULL
either	NULL
IxBaS32A	NULL
or	NULL
p65	NULL
(	NULL
A	NULL
)	NULL
C	NULL
resulted	NULL
in	NULL
a	NULL
marked	NULL
reduction	NULL
in	NULL
the	NULL
number	NULL
of	NULL
GFP-expressing	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

54	NULL
)	NULL
.	NULL

Quantitation	NULL
revealed	NULL
a	NULL
reduction	NULL
by	NULL
83	NULL
%	NULL
and	NULL
59	NULL
%	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

FITC-labeled	NULL
annexin-V	NULL
binding	NULL
experiments	NULL
carried	NULL
out	NULL
on	NULL
individual	NULL
cells	NULL
in	NULL
which	NULL
both	NULL
dominant	NULL
negative	NULL
mutants	NULL
were	NULL
transiently	NULL
expressed	NULL
revealed	NULL
a	NULL
corresponding	NULL
increase	NULL
in	NULL
the	NULL
number	NULL
of	NULL
apoptotic	NULL
cells	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

DISCUSSION	NULL
Our	NULL
results	NULL
provide	NULL
direct	NULL
evidence	NULL
that	NULL
T	NULL
cells	NULL
transformed	NULL
by	NULL
T.	NULL
parva	NULL
require	NULL
an	NULL
intact	NULL
,	NULL
constitutively	NULL
activated	NULL
NF-kB	NULL
pathway	NULL
to	NULL
escape	NULL
apoptosis	NULL
.	NULL

The	NULL
transformation	NULL
of	NULL
eukaryotic	NULL
cells	NULL
by	NULL
viruses	NULL
is	NULL
a	NULL
well-documented	NULL
phenomenon	NULL
(	NULL
54	NULL
)	NULL
,	NULL
but	NULL
among	NULL
parasites	NULL
,	NULL
Theileria	NULL
is	NULL
unique	NULL
in	NULL
its	NULL
ability	NULL
to	NULL
transform	NULL
the	NULL
cells	NULL
it	NULL
infects	NULL
(	NULL
9	NULL
,	NULL
15	NULL
,	NULL
55	NULL
)	NULL
and	NULL
is	NULL
also	NULL
the	NULL
only	NULL
eukaryote	NULL
known	NULL
to	NULL
transform	NULL
another	NULL
eukaryote	NULL
.	NULL

Most	NULL
normal	NULL
cells	NULL
depend	NULL
on	NULL
tissue	NULL
environment-specific	NULL
factors	NULL
to	NULL
maintain	NULL
viability	NULL
and	NULL
proliferate	NULL
(	NULL
56	NULL
,	NULL
57	NULL
)	NULL
.	NULL

T.	NULL
parva-transformed	NULL
T	NULL
cells	NULL
appear	NULL
to	NULL
circumvent	NULL
these	NULL
homeostatic	NULL
mechanisms	NULL
by	NULL
becoming	NULL
independent	NULL
of	NULL
antigenic	NULL
stimulation	NULL
and	NULL
exogenous	NULL
growth	NULL
factors	NULL
(	NULL
4-6	NULL
)	NULL
,	NULL
which	NULL
allows	NULL
them	NULL
to	NULL
proliferate	NULL
in	NULL
nonlymphoid	NULL
as	NULL
well	NULL
as	NULL
lymphoid	NULL
tissues	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Transformation	NULL
is	NULL
normally	NULL
an	NULL
irreversible	NULL
event	NULL
,	NULL
and	NULL
acquiring	NULL
resistance	NULL
to	NULL
apoptotic	NULL
cell	NULL
death	NULL
is	NULL
an	NULL
essential	NULL
step	NULL
in	NULL
the	NULL
progression	NULL
to	NULL
malignancy	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Transformation	NULL
by	NULL
T.	NULL
parve	NULL
differs	NULL
from	NULL
other	NULL
transformation	NULL
processes	NULL
in	NULL
that	NULL
it	NULL
is	NULL
reversible	NULL
.	NULL

Our	NULL
findings	NULL
show	NULL
,	NULL
however	NULL
,	NULL
that	NULL
T	NULL
cells	NULL
transformed	NULL
in	NULL
this	NULL
manner	NULL
do	NULL
not	NULL
escape	NULL
the	NULL
requirement	NULL
for	NULL
protection	NULL
against	NULL
spontaneous	NULL
apoptosis	NULL
,	NULL
and	NULL
that	NULL
protection	NULL
is	NULL
achieved	NULL
by	NULL
constitutive	NULL
NF-KB	NULL
activation	NULL
.	NULL

In	NULL
this	NULL
respect	NULL
,	NULL
7.	NULL
parva	NULL
T	NULL
cells	NULL
closely	NULL
resemble	NULL
murine	NULL
immature	NULL
B	NULL
cell	NULL
lymphoma	NULL
WEHI	NULL
231	NULL
cells	NULL
(	NULL
58	NULL
)	NULL
and	NULL
human	NULL
cutaneous	NULL
T	NULL
cell	NULL
lymphoma	NULL
HuT-78	NULL
cells	NULL
(	NULL
59	NULL
)	NULL
,	NULL
which	NULL
also	NULL
appear	NULL
to	NULL
require	NULL
NF-kB	NULL
to	NULL
become	NULL
resistant	NULL
to	NULL
spontaneous	NULL
apoptosis	NULL
.	NULL

It	NULL
recently	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
oncogenic	NULL
Ras	NULL
initiates	NULL
not	NULL
only	NULL
transformation	NULL
in	NULL
NIH	NULL
3T3	NULL
cells	NULL
,	NULL
but	NULL
also	NULL
an	NULL
apoptotic	NULL
response	NULL
that	NULL
is	NULL
suppressed	NULL
by	NULL
the	NULL
Ras-induced	NULL
activation	NULL
of	NULL
NF-KB	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
the	NULL
same	NULL
way	NULL
that	NULL
the	NULL
ability	NULL
of	NULL
oncogenic	NULL
Ras	NULL
to	NULL
transform	NULL
cells	NULL
depends	NULL
on	NULL
its	NULL
capacity	NULL
to	NULL
activate	NULL
NF-kB	NULL
,	NULL
7.	NULL
parva-induced	NULL
T-cell	NULL
transformation	NULL
requires	NULL
parasite-dependent	NULL
constitutive	NULL
NF-KB	NULL
activation	NULL
.	NULL

The	NULL
intralymphocytic	NULL
schizont	NULL
stage	NULL
of	NULL
T.	NULL
parva	NULL
is	NULL
the	NULL
only	NULL
proliferative	NULL
stage	NULL
in	NULL
the	NULL
mammalian	NULL
part	NULL
of	NULL
the	NULL
parasite	NULL
life	NULL
cycle	NULL
.	NULL

Parasite	NULL
survival	NULL
therefore	NULL
strictly	NULL
depends	NULL
on	NULL
persistently	NULL
infected	NULL
T	NULL
cells	NULL
.	NULL

By	NULL
analogy	NULL
to	NULL
virus-infected	NULL
cells	NULL
(	NULL
60	NULL
,	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
61	NULL
)	NULL
,	NULL
early	NULL
apoptosis	NULL
would	NULL
severely	NULL
limit	NULL
parasite	NULL
production	NULL
and	NULL
eliminate	NULL
the	NULL
spread	NULL
of	NULL
parasites	NULL
in	NULL
the	NULL
host	NULL
.	NULL

Similar	NULL
strategies	NULL
appear	NULL
to	NULL
be	NULL
used	NULL
by	NULL
bacteria	NULL
,	NULL
and	NULL
in	NULL
this	NULL
context	NULL
,	NULL
NF-KB	NULL
activation	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
guarantee	NULL
cell	NULL
survival	NULL
during	NULL
Rickettsia	NULL
rickettsii	NULL
infection	NULL
(	NULL
62	NULL
)	NULL
.	NULL

T.	NULL
parva-induced	NULL
NF-KB	NULL
activation	NULL
may	NULL
protect	NULL
T	NULL
cells	NULL
at	NULL
more	NULL
than	NULL
one	NULL
level	NULL
.	NULL

For	NULL
example	NULL
,	NULL
T.	NULL
parva-transformed	NULL
T	NULL
cells	NULL
acquire	NULL
solid	NULL
resistance	NULL
to	NULL
tumor	NULL
necrosis	NULL
factor-induced	NULL
cytotoxicity	NULL
(	NULL
63	NULL
)	NULL
,	NULL
and	NULL
observations	NULL
made	NULL
in	NULL
several	NULL
other	NULL
systems	NULL
(	NULL
22-25	NULL
)	NULL
strongly	NULL
suggest	NULL
that	NULL
this	NULL
resistance	NULL
is	NULL
most	NULL
likely	NULL
to	NULL
be	NULL
mediated	NULL
by	NULL
NF-kB	NULL
.	NULL

Interestingly	NULL
,	NULL
NF-kB	NULL
activation	NULL
recently	NULL
has	NULL
been	NULL
demonstrated	NULL
for	NULL
two	NULL
other	NULL
apicomplexan	NULL
parasites	NULL
,	NULL
Plasmo-dium	NULL
and	NULL
Toxoplasma	NULL
(	NULL
64-66	NULL
)	NULL
,	NULL
raising	NULL
the	NULL
possibility	NULL
that	NULL
this	NULL
is	NULL
a	NULL
common	NULL
characteristic	NULL
of	NULL
parasites	NULL
belonging	NULL
to	NULL
the	NULL
phylum	NULL
Apicomplexa	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
an	NULL
NF-	NULL
«	NULL
B-dependent	NULL
antiapoptotic	NULL
pathway	NULL
exists	NULL
in	NULL
7.	NULL
parva-transformed	NULL
T	NULL
cells	NULL
does	NULL
not	NULL
exclude	NULL
the	NULL
existence	NULL
of	NULL
other	NULL
antiapoptotic	NULL
mecha-nisms	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
initial	NULL
observations	NULL
in	NULL
our	NULL
laboratory	NULL
indicate	NULL
that	NULL
the	NULL
death	NULL
receptor	NULL
FAS/APO-1	NULL
is	NULL
down-regulated	NULL
in	NULL
7.	NULL
parve-transformed	NULL
T	NULL
cells	NULL
,	NULL
compared	NULL
with	NULL
uninfected	NULL
Con	NULL
A-stimulated	NULL
T	NULL
cells	NULL
.	NULL

T.	NULL
annulata	NULL
transforms	NULL
cells	NULL
of	NULL
monocyte/macrophage-	NULL
or	NULL
B-cell	NULL
lineage	NULL
,	NULL
and	NULL
NF-KB	NULL
also	NULL
is	NULL
activated	NULL
in	NULL
these	NULL
cell	NULL
lines	NULL
.	NULL

It	NULL
will	NULL
be	NULL
interesting	NULL
to	NULL
find	NULL
out	NULL
whether	NULL
such	NULL
cells	NULL
also	NULL
rely	NULL
on	NULL
a	NULL
NF-	NULL
«	NULL
B-dependent	NULL
mechanism	NULL
to	NULL
avoid	NULL
apoptosis	NULL
.	NULL

That	NULL
T.	NULL
parva	NULL
may	NULL
not	NULL
be	NULL
alone	NULL
among	NULL
parasites	NULL
to	NULL
induce	NULL
resistance	NULL
to	NULL
apoptosis	NULL
is	NULL
suggested	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
cells	NULL
infected	NULL
with	NULL
Toxoplasma	NULL
gondii	NULL
are	NULL
resistant	NULL
to	NULL
multiple	NULL
inducers	NULL
of	NULL
apoptosis	NULL
(	NULL
67	NULL
)	NULL
,	NULL
and	NULL
it	NULL
will	NULL
be	NULL
of	NULL
interest	NULL
to	NULL
determine	NULL
whether	NULL
NF-KB	NULL
activation	NULL
induced	NULL
by	NULL
7.	NULL
gondii	NULL
infection	NULL
(	NULL
64	NULL
)	NULL
also	NULL
is	NULL
involved	NULL
in	NULL
these	NULL
processes	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
during	NULL
the	NULL
course	NULL
of	NULL
evolution	NULL
,	NULL
parasites	NULL
have	NULL
developed	NULL
a	NULL
broad	NULL
spectrum	NULL
of	NULL
strategies	NULL
to	NULL
survive	NULL
immune	NULL
attack	NULL
,	NULL
including	NULL
antigenic	NULL
variation	NULL
,	NULL
molecular	NULL
mimicry	NULL
,	NULL
and	NULL
resistance	NULL
to	NULL
immunological	NULL
effector	NULL
mechanisms	NULL
(	NULL
68	NULL
)	NULL
.	NULL

7.	NULL
parva	NULL
has	NULL
taken	NULL
this	NULL
to	NULL
the	NULL
extreme	NULL
,	NULL
first	NULL
,	NULL
by	NULL
taking	NULL
up	NULL
residence	NULL
inside	NULL
those	NULL
cells	NULL
that	NULL
have	NULL
evolved	NULL
to	NULL
destroy	NULL
invading	NULL
organisms	NULL
and	NULL
,	NULL
second	NULL
,	NULL
by	NULL
inducing	NULL
uncontrolled	NULL
proliferation	NULL
of	NULL
the	NULL
host	NULL
cell	NULL
and	NULL
activating	NULL
the	NULL
antiapoptotic	NULL
pathways	NULL
that	NULL
are	NULL
required	NULL
to	NULL
maintain	NULL
the	NULL
transformed	NULL
phe-notype	NULL
.	NULL

I.	NULL
Roditi	NULL
,	NULL
G.	NULL
Bertoni	NULL
,	NULL
E.	NULL
Peterhans	NULL
,	NULL
E.	NULL
Miller	NULL
,	NULL
and	NULL
M.	NULL
Schweizer	NULL
are	NULL
thanked	NULL
for	NULL
comments	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
Swiss	NULL
National	NULL
Science	NULL
Foundation	NULL
(	NULL
SNSF	NULL
No	NULL
.	NULL

31.43328.95	NULL
to	NULL
D.A.E.D	NULL
.	NULL
)	NULL

,	NULL
the	NULL
Federal	NULL
Office	NULL
for	NULL
Education	NULL
and	NULL
Science	NULL
(	NULL
European	NULL
Union	NULL
collaboration	NULL
Grant	NULL
No	NULL
.	NULL

95.0696	NULL
)	NULL
,	NULL
and	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Swiss	NULL
Cancer	NULL
League	NULL
(	NULL
KFS	NULL
625-2-1998	NULL
)	NULL
.	NULL

P.C.F	NULL
.	NULL

is	NULL
a	NULL
recipient	NULL
of	NULL
Swiss	NULL
National	NULL
Science	NULL
Foundation	NULL
Stipend	NULL
31.44407.95	NULL
for	NULL
the	NULL
MD-Ph.D	NULL
program	NULL
.	NULL

1	NULL
.	NULL

-	NULL
Morrison	NULL
,	NULL
W.	NULL
I.	NULL
,	NULL
Lalor	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Goddeeris	NULL
,	NULL
B.	NULL
M.	NULL
&	NULL
Teale	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
in	NULL
Parasite	NULL
Antigens	NULL
,	NULL
Toward	NULL
New	NULL
Strategies	NULL
for	NULL
Vaccines	NULL
,	NULL
ed	NULL
.	NULL

Pearson	NULL
,	NULL
T.	NULL
W.	NULL
(	NULL
Dekker	NULL
,	NULL
New	NULL
York	NULL
)	NULL
,	NULL
pp	NULL
.	NULL

167-213	NULL
.	NULL

2	NULL
.	NULL

Brown	NULL
,	NULL
C.	NULL
G.	NULL
,	NULL
Stagg	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Purnell	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Kanhai	NULL
,	NULL
G.	NULL
K.	NULL
&	NULL
Payne	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1973	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
245	NULL
,	NULL
101-103	NULL
.	NULL

3	NULL
.	NULL

Baldwin	NULL
,	NULL
C.	NULL
L.	NULL
&	NULL
Teale	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

17	NULL
,	NULL
1859-1862	NULL
.	NULL

4	NULL
.	NULL

-	NULL
Galley	NULL
,	NULL
Y.	NULL
,	NULL
Hagens	NULL
,	NULL
G.	NULL
,	NULL
Glaser	NULL
,	NULL
I.	NULL
,	NULL
Davis	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
Eichhorn	NULL
,	NULL
M.	NULL
&	NULL
Dobbelaere	NULL
,	NULL
D.	NULL
A.	NULL
E.	NULL
(	NULL
1997	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
,	NULL
5119-5124	NULL
.	NULL

5	NULL
.	NULL

Dobbelaere	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Coquerelle	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Roditi	NULL
,	NULL
I.	NULL
J.	NULL
,	NULL
Eichhorn	NULL
,	NULL
M.	NULL
&	NULL
Williams	NULL
,	NULL
R.	NULL
O	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85	NULL
,	NULL
4730-4734	NULL
.	NULL

6	NULL
.	NULL

Brown	NULL
,	NULL
W.	NULL
C.	NULL
&	NULL
Logan	NULL
,	NULL
K.	NULL
S.	NULL
(	NULL
1986	NULL
)	NULL
Parasite	NULL
Immunol	NULL
.	NULL

8	NULL
,	NULL
189-192	NULL
.	NULL

7	NULL
.	NULL

Irvin	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Brown	NULL
,	NULL
C.	NULL
G.	NULL
,	NULL
Kanhai	NULL
,	NULL
G.	NULL
K.	NULL
&	NULL
Stagg	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

(	NULL
1975	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
255	NULL
,	NULL
713-714	NULL
.	NULL

8	NULL
.	NULL

-	NULL
Morrison	NULL
,	NULL
W.	NULL
I.	NULL
,	NULL
Buscher	NULL
,	NULL
G.	NULL
,	NULL
Murray	NULL
,	NULL
M.	NULL
,	NULL
Emery	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Masake	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Cook	NULL
,	NULL
R.	NULL
H.	NULL
&	NULL
Wells	NULL
,	NULL
P.	NULL
W.	NULL
(	NULL
1981	NULL
)	NULL
Exp	NULL
.	NULL

Parasitol	NULL
.	NULL

52	NULL
,	NULL
248-260	NULL
.	NULL

9	NULL
.	NULL

Eichhorn	NULL
,	NULL
M.	NULL
&	NULL
Dobbelaere	NULL
,	NULL
D.	NULL
A.	NULL
E.	NULL
(	NULL
1994	NULL
)	NULL
Parasitol	NULL
.	NULL

Today	NULL
10	NULL
,	NULL
469-472	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

15	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

Cell	NULL
Biology	NULL
:	NULL
Heussler	NULL
et	NULL
al	NULL
.	NULL

Fich	NULL
,	NULL
C.	NULL
,	NULL
Klauenberg	NULL
,	NULL
U.	NULL
,	NULL
Fleischer	NULL
,	NULL
B	NULL
.	NULL

&	NULL
Broker	NULL
,	NULL
B.	NULL
M.	NULL
(	NULL
1998	NULL
)	NULL
Parasitology	NULL
117	NULL
,	NULL
107-115	NULL
.	NULL

Botteron	NULL
,	NULL
C.	NULL
&	NULL
Dobbelaere	NULL
,	NULL
D.	NULL
(	NULL
1998	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

246	NULL
,	NULL
418-421.	NULL
ole-MoiYoi	NULL
,	NULL
O.	NULL
K.	NULL
,	NULL
Brown	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
Iams	NULL
,	NULL
K.	NULL
P.	NULL
,	NULL
Nayar	NULL
,	NULL
A.	NULL
,	NULL
Tsukamoto	NULL
,	NULL
T.	NULL
&	NULL
Macklin	NULL
,	NULL
M.	NULL
D.	NULL
(	NULL
1993	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

12	NULL
,	NULL
1621-1631.	NULL
ole-MoiYoi	NULL
,	NULL
O.	NULL
K.	NULL
(	NULL
1995	NULL
)	NULL
Science	NULL
267	NULL
,	NULL
834-836	NULL
.	NULL

Seldin	NULL
,	NULL
D.	NULL
C.	NULL
&	NULL
Leder	NULL
,	NULL
P.	NULL
(	NULL
1995	NULL
)	NULL
Science	NULL
267	NULL
,	NULL
894-897	NULL
.	NULL

Chaussepied	NULL
,	NULL
M.	NULL
&	NULL
Langsley	NULL
,	NULL
G.	NULL
(	NULL
1996	NULL
)	NULL
Res	NULL
.	NULL

Immunol	NULL
.	NULL

147	NULL
,	NULL
127-138	NULL
.	NULL

Hudson	NULL
,	NULL
A.	NULL
T.	NULL
,	NULL
Randall	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
Fry	NULL
,	NULL
M.	NULL
,	NULL
Ginger	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Hill	NULL
,	NULL
B.	NULL
,	NULL
Latter	NULL
,	NULL
V.	NULL
S.	NULL
,	NULL
McHardy	NULL
,	NULL
N.	NULL
&	NULL
Williams	NULL
,	NULL
R.	NULL
B	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Parasitology	NULL
90	NULL
,	NULL
45-55	NULL
.	NULL

Osborne	NULL
,	NULL
B	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

8	NULL
,	NULL
245-254	NULL
.	NULL

Evan	NULL
,	NULL
G.	NULL
(	NULL
1997	NULL
)	NULL
Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
71	NULL
,	NULL
709-711	NULL
.	NULL

Wyllie	NULL
,	NULL
A.	NULL
H.	NULL
(	NULL
1997	NULL
)	NULL
Eur	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

73	NULL
,	NULL
189-197	NULL
.	NULL

Mayo	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
Wang	NULL
,	NULL
C.	NULL
Y.	NULL
,	NULL
Cogswell	NULL
,	NULL
P.	NULL
C.	NULL
,	NULL
Rogers	NULL
Graham	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Lowe	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
Der	NULL
,	NULL
C.	NULL
J	NULL
.	NULL

&	NULL
Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Science	NULL
278	NULL
,	NULL
1812-1815	NULL
.	NULL

Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

14	NULL
,	NULL
649-683	NULL
.	NULL

Van	NULL
Antwerp	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Martin	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Kafri	NULL
,	NULL
T.	NULL
,	NULL
Green	NULL
,	NULL
D.	NULL
R.	NULL
&	NULL
Verma	NULL
,	NULL
I.	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
Science	NULL
274	NULL
,	NULL
787-789	NULL
.	NULL

Wang	NULL
,	NULL
C.	NULL
Y.	NULL
,	NULL
Mayo	NULL
,	NULL
M.	NULL
W.	NULL
&	NULL
Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Jr.	NULL
(	NULL
1996	NULL
)	NULL
Science	NULL
274	NULL
,	NULL
784-787	NULL
.	NULL

Beg	NULL
,	NULL
A	NULL
.	NULL

A	NULL
.	NULL

&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1996	NULL
)	NULL
Science	NULL
274	NULL
,	NULL
782-784	NULL
.	NULL

Liu	NULL
,	NULL
Z.	NULL
G.	NULL
,	NULL
Hsu	NULL
,	NULL
H.	NULL
,	NULL
Goeddel	NULL
,	NULL
D.	NULL
V.	NULL
&	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
Cell	NULL
87	NULL
,	NULL
565-576	NULL
.	NULL

Arsura	NULL
,	NULL
M.	NULL
,	NULL
Wu	NULL
,	NULL
M.	NULL
&	NULL
Sonenshein	NULL
,	NULL
G.	NULL
E.	NULL
(	NULL
1996	NULL
)	NULL
Immunity	NULL
5	NULL
,	NULL
31-40	NULL
.	NULL

Bertrand	NULL
,	NULL
F.	NULL
,	NULL
Atfi	NULL
,	NULL
A.	NULL
,	NULL
Cadoret	NULL
,	NULL
A.	NULL
,	NULL
L'Allemain	NULL
,	NULL
G.	NULL
,	NULL
Robin	NULL
,	NULL
H.	NULL
,	NULL
Lascols	NULL
,	NULL
O.	NULL
,	NULL
Capeau	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Cherqui	NULL
,	NULL
G.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273	NULL
,	NULL
2931-2938	NULL
.	NULL

Baichwal	NULL
,	NULL
V.	NULL
R.	NULL
&	NULL
Bacuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Curr	NULL
.	NULL

Biol	NULL
.	NULL

7	NULL
,	NULL
R94-R96	NULL
.	NULL

Chu	NULL
,	NULL
Z.	NULL
L.	NULL
,	NULL
McKinsey	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
Liu	NULL
,	NULL
L.	NULL
,	NULL
Gentry	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Malim	NULL
,	NULL
M.	NULL
H.	NULL
&	NULL
Ballard	NULL
,	NULL
D.	NULL
W.	NULL
(	NULL
1997	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
94	NULL
,	NULL
10057-10062	NULL
.	NULL

Liston	NULL
,	NULL
P.	NULL
,	NULL
Roy	NULL
,	NULL
N.	NULL
,	NULL
Tamai	NULL
,	NULL
K.	NULL
,	NULL
Lefebvre	NULL
,	NULL
C.	NULL
,	NULL
Baird	NULL
,	NULL
S.	NULL
,	NULL
Cherton-Horvat	NULL
,	NULL
G.	NULL
,	NULL
Farahani	NULL
,	NULL
R.	NULL
,	NULL
McLean	NULL
,	NULL
M.	NULL
,	NULL
Ikeda	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
MacKenzie	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Korneluk	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1996	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
379	NULL
,	NULL
349-353	NULL
.	NULL

Stehlik	NULL
,	NULL
C.	NULL
,	NULL
de	NULL
Martin	NULL
,	NULL
R.	NULL
,	NULL
Kumabashiri	NULL
,	NULL
I.	NULL
,	NULL
Schmid	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Binder	NULL
,	NULL
B.	NULL
R.	NULL
&	NULL
Lipp	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

188	NULL
,	NULL
211-216	NULL
.	NULL

Wang	NULL
,	NULL
C.	NULL
Y.	NULL
,	NULL
Mayo	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
Korneluk	NULL
,	NULL
R.	NULL
G.	NULL
,	NULL
Goeddel	NULL
,	NULL
D.	NULL
V.	NULL
&	NULL
Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Science	NULL
281	NULL
,	NULL
1680-1683	NULL
.	NULL

Devereaux	NULL
,	NULL
Q.	NULL
L.	NULL
,	NULL
Takahashi	NULL
,	NULL
R.	NULL
,	NULL
Salvesen	NULL
,	NULL
G.	NULL
S.	NULL
&	NULL
Reed	NULL
,	NULL
J.	NULL
C.	NULL
(	NULL
1997	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
388	NULL
,	NULL
300-304	NULL
.	NULL

Stancovski	NULL
,	NULL
I	NULL
.	NULL

&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1997	NULL
)	NULL
Cell	NULL
91	NULL
,	NULL
299-302	NULL
.	NULL

Ivanov	NULL
,	NULL
V.	NULL
,	NULL
Stein	NULL
,	NULL
B.	NULL
,	NULL
Baumann	NULL
,	NULL
L.	NULL
,	NULL
Dobbelaere	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Herrlich	NULL
,	NULL
P.	NULL
&	NULL
Williams	NULL
,	NULL
R.	NULL
O	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

9	NULL
,	NULL
4677-4686	NULL
.	NULL

Palmer	NULL
,	NULL
G.	NULL
H.	NULL
,	NULL
Machado	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Fernandez	NULL
,	NULL
P.	NULL
,	NULL
Heussler	NULL
,	NULL
V.	NULL
,	NULL
Perinat	NULL
,	NULL
T.	NULL
&	NULL
Dobbelaere	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
,	NULL
12527-12532	NULL
.	NULL

Dobbelaere	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Prospero	NULL
,	NULL
T.	NULL
D.	NULL
,	NULL
Roditi	NULL
,	NULL
I.	NULL
J.	NULL
,	NULL
Kelke	NULL
,	NULL
C.	NULL
,	NULL
Baumann	NULL
,	NULL
I.	NULL
,	NULL
Eichhorn	NULL
,	NULL
M.	NULL
,	NULL
Williams	NULL
,	NULL
R.	NULL
O.	NULL
,	NULL
Ahmed	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Baldwin	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Clevers	NULL
,	NULL
H.	NULL
,	NULL
ef	NULL
al	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Infect	NULL
.	NULL

Immun	NULL
.	NULL

58	NULL
,	NULL
3847-3855	NULL
.	NULL

Coquerelle	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Eichhorn	NULL
,	NULL
M.	NULL
,	NULL
Magnuson	NULL
,	NULL
N.	NULL
S.	NULL
,	NULL
Reeves	NULL
,	NULL
R.	NULL
,	NULL
Williams	NULL
,	NULL
R.	NULL
O	NULL
.	NULL

&	NULL
Dobbelaere	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

19	NULL
,	NULL
655-659	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

55	NULL
,	NULL
56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

68	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
7317	NULL
Heussler	NULL
,	NULL
V.	NULL
T.	NULL
,	NULL
Eichhorn	NULL
,	NULL
M.	NULL
,	NULL
Reeves	NULL
,	NULL
R.	NULL
,	NULL
Magnuson	NULL
,	NULL
N.	NULL
S.	NULL
,	NULL
Williams	NULL
,	NULL
R.	NULL
O	NULL
.	NULL

&	NULL
Dobbelaere	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

149	NULL
,	NULL
562-567	NULL
.	NULL

Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Science	NULL
267	NULL
,	NULL
1456-1462	NULL
.	NULL

Bold	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Termuhlen	NULL
,	NULL
P.	NULL
M.	NULL
&	NULL
McConkey	NULL
,	NULL
D.	NULL
J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Surg	NULL
.	NULL

Oncol	NULL
.	NULL

6	NULL
,	NULL
133-142	NULL
.	NULL

Lyons	NULL
,	NULL
S.	NULL
K.	NULL
&	NULL
Clarke	NULL
,	NULL
A.	NULL
R.	NULL
(	NULL
1997	NULL
)	NULL
Br	NULL
.	NULL

Med	NULL
.	NULL

Bull	NULL
.	NULL

53	NULL
,	NULL
554-569	NULL
.	NULL

Chen	NULL
,	NULL
C.	NULL
G.	NULL
,	NULL
Malliaros	NULL
,	NULL
J.	NULL
,	NULL
Katerelos	NULL
,	NULL
M.	NULL
,	NULL
d'Apice	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

&	NULL
Pearse	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Mol	NULL
.	NULL

Immunol	NULL
.	NULL

33	NULL
,	NULL
57-61	NULL
.	NULL

Stauber	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
Horie	NULL
,	NULL
K.	NULL
,	NULL
Carney	NULL
,	NULL
P.	NULL
,	NULL
Hudson	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Tarasova	NULL
,	NULL
N.	NULL
I.	NULL
,	NULL
Gaitanaris	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

&	NULL
Pavlakis	NULL
,	NULL
G.	NULL
N.	NULL
(	NULL
1998	NULL
)	NULL
BioTechniques	NULL
24	NULL
,	NULL
462-466	NULL
,	NULL
468-471	NULL
.	NULL

Jung	NULL
,	NULL
S.	NULL
,	NULL
Yaron	NULL
,	NULL
A.	NULL
,	NULL
Alkalay	NULL
,	NULL
L.	NULL
,	NULL
Hatzubai	NULL
,	NULL
A.	NULL
,	NULL
Avraham	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Ben	NULL
Neriah	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Ann	NULL
.	NULL

N.Y.	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

766	NULL
,	NULL
245-252	NULL
.	NULL

Guesdon	NULL
,	NULL
F.	NULL
,	NULL
Ikebe	NULL
,	NULL
T.	NULL
,	NULL
Stylianou	NULL
,	NULL
E.	NULL
,	NULL
Warwick	NULL
Davies	NULL
,	NULL
J.	NULL
,	NULL
Haskill	NULL
,	NULL
S.	NULL
&	NULL
Saklatvala	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

307	NULL
,	NULL
287-295	NULL
.	NULL

Pierce	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Schoenleber	NULL
,	NULL
R.	NULL
,	NULL
Jesmok	NULL
,	NULL
G.	NULL
,	NULL
Best	NULL
,	NULL
J.	NULL
,	NULL
Moore	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Collins	NULL
,	NULL
T.	NULL
&	NULL
Gerritsen	NULL
,	NULL
M.	NULL
E.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
,	NULL
21096-21103	NULL
.	NULL

Verhoven	NULL
,	NULL
B.	NULL
,	NULL
Schlegel	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

&	NULL
Williamson	NULL
,	NULL
P.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182	NULL
,	NULL
1597-1601	NULL
.	NULL

Thiagarajan	NULL
,	NULL
P.	NULL
&	NULL
Tait	NULL
,	NULL
J.	NULL
F.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
,	NULL
17420-17423	NULL
.	NULL

Palombella	NULL
,	NULL
V.	NULL
J.	NULL
,	NULL
Rando	NULL
,	NULL
O.	NULL
J.	NULL
,	NULL
Goldberg	NULL
,	NULL
A.	NULL
L.	NULL
&	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
78	NULL
,	NULL
773-785	NULL
.	NULL

Chen	NULL
,	NULL
Z.	NULL
,	NULL
Hagler	NULL
,	NULL
J.	NULL
,	NULL
Palombella	NULL
,	NULL
V.	NULL
J.	NULL
,	NULL
Melandri	NULL
,	NULL
F.	NULL
,	NULL
Scherer	NULL
,	NULL
D.	NULL
,	NULL
Ballard	NULL
,	NULL
D.	NULL
&	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

9	NULL
,	NULL
1586-1597	NULL
.	NULL

Kumar	NULL
,	NULL
S.	NULL
,	NULL
Kinoshita	NULL
,	NULL
M.	NULL
,	NULL
Noda	NULL
,	NULL
M.	NULL
,	NULL
Copeland	NULL
,	NULL
N.	NULL
G.	NULL
&	NULL
Jenkins	NULL
,	NULL
N.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

8	NULL
,	NULL
1613-1626	NULL
.	NULL

Hsu	NULL
,	NULL
H.	NULL
,	NULL
Xiong	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Goeddel	NULL
,	NULL
D.	NULL
V.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
81	NULL
,	NULL
495-504	NULL
.	NULL

Vousden	NULL
,	NULL
K.	NULL
H.	NULL
&	NULL
Farrell	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Br	NULL
.	NULL

Med	NULL
.	NULL

Bull	NULL
.	NULL

50	NULL
,	NULL
560-581	NULL
.	NULL

Williams	NULL
,	NULL
R.	NULL
O	NULL
.	NULL

&	NULL
Dobbelaere	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Semin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

4	NULL
,	NULL
363-371	NULL
.	NULL

Raff	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Barres	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Burne	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Coles	NULL
,	NULL
H.	NULL
S.	NULL
,	NULL
Ishizaki	NULL
,	NULL
Y	NULL
.	NULL

&	NULL
Jacobson	NULL
,	NULL
M.	NULL
D.	NULL
(	NULL
1993	NULL
)	NULL
Science	NULL
262	NULL
,	NULL
695-700	NULL
.	NULL

Williams	NULL
,	NULL
G.	NULL
T.	NULL
,	NULL
Smith	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Spooncer	NULL
,	NULL
E.	NULL
,	NULL
Dexter	NULL
,	NULL
T.	NULL
M.	NULL
&	NULL
Taylor	NULL
,	NULL
D.	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
343	NULL
,	NULL
76-79	NULL
.	NULL

Wu	NULL
,	NULL
M.	NULL
,	NULL
Lee	NULL
,	NULL
H.	NULL
,	NULL
Bellas	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Schauer	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Arsura	NULL
,	NULL
M.	NULL
,	NULL
Katz	NULL
,	NULL
D.	NULL
,	NULL
FitzGerald	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Rothstein	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
Sherr	NULL
,	NULL
D.	NULL
H.	NULL
&	NULL
Sonenshein	NULL
,	NULL
G.	NULL
E.	NULL
(	NULL
1996	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

15	NULL
,	NULL
4682-4690	NULL
.	NULL

Giri	NULL
,	NULL
D.	NULL
K.	NULL
&	NULL
Aggarwal	NULL
,	NULL
B	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273	NULL
,	NULL
14008-14014	NULL
.	NULL

Teodoro	NULL
,	NULL
J.	NULL
G.	NULL
&	NULL
Branton	NULL
,	NULL
P.	NULL
E.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

71	NULL
,	NULL
1739-1746	NULL
.	NULL

Tschopp	NULL
,	NULL
J.	NULL
,	NULL
Thome	NULL
,	NULL
M.	NULL
,	NULL
Hofmann	NULL
,	NULL
K.	NULL
&	NULL
Meinl	NULL
,	NULL
E.	NULL
(	NULL
1998	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Genet	NULL
.	NULL

Dev	NULL
.	NULL

8	NULL
,	NULL
82-87	NULL
.	NULL

Clifton	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
Goss	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Sahni	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
van	NULL
Antwerp	NULL
,	NULL
D.	NULL
,	NULL
Baggs	NULL
,	NULL
R.	NULL
B.	NULL
,	NULL
Marder	NULL
,	NULL
V.	NULL
J.	NULL
,	NULL
Silverman	NULL
,	NULL
D.	NULL
J	NULL
.	NULL

&	NULL
Sporn	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
95	NULL
,	NULL
4646-4651	NULL
.	NULL

DeMartini	NULL
,	NULL
J.	NULL
C.	NULL
&	NULL
Baldwin	NULL
,	NULL
C.	NULL
L.	NULL
(	NULL
1991	NULL
)	NULL
Infect	NULL
.	NULL

Immun	NULL
.	NULL

59	NULL
,	NULL
4540-4546	NULL
.	NULL

Gazzinelli	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
Sher	NULL
,	NULL
A.	NULL
,	NULL
Cheever	NULL
,	NULL
A.	NULL
,	NULL
Gerstberger	NULL
,	NULL
S.	NULL
,	NULL
Martin	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

&	NULL
Dickie	NULL
,	NULL
P.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183	NULL
,	NULL
1645-1655	NULL
.	NULL

Schofield	NULL
,	NULL
L.	NULL
,	NULL
Novakovic	NULL
,	NULL
S.	NULL
,	NULL
Gerold	NULL
,	NULL
P.	NULL
,	NULL
Schwarz	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
McConville	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

&	NULL
Tachado	NULL
,	NULL
S.	NULL
D.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

156	NULL
,	NULL
1886-1896	NULL
.	NULL

Tachado	NULL
,	NULL
S.	NULL
D.	NULL
,	NULL
Gerold	NULL
,	NULL
P.	NULL
,	NULL
McConville	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Baldwin	NULL
,	NULL
T.	NULL
,	NULL
Quilici	NULL
,	NULL
D.	NULL
,	NULL
Schwarz	NULL
,	NULL
R.	NULL
T.	NULL
&	NULL
Schofield	NULL
,	NULL
L.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

156	NULL
,	NULL
1897-1907	NULL
.	NULL

Nash	NULL
,	NULL
P.	NULL
B.	NULL
,	NULL
Purner	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
Leon	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Clarke	NULL
,	NULL
P.	NULL
,	NULL
Duke	NULL
,	NULL
R.	NULL
C.	NULL
&	NULL
Curiel	NULL
,	NULL
T.	NULL
J	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

160	NULL
,	NULL
1824-1830	NULL
.	NULL

Beverley	NULL
,	NULL
S.	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
Cell	NULL
87	NULL
,	NULL
787-789	NULL
.	NULL

